Overexpression of matrix metalloproteinase 11 in thai prostatic adenocarcinoma is associated with poor survival

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 3331-3335

  Nonsrijun, Nongnuch ^a   Mitchai, Jumphol ^a   Brown, Kamoltip ^b   Leksomboon, Ratana ^c   Tuamsuk, Panya ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b Khon Kaen University   (Thailand)

^c UBON RATCHATHANI UNIVERSITY   (Thailand)

Author keywords

Matrix metalloproteinase 11; Prognostic significance; Prostatic adenocarcinoma; Survival time

Indexed keywords

MMP11 PROTEIN, HUMAN; PROSTATE SPECIFIC ANTIGEN; STROMELYSIN 3; TUMOR MARKER;

ADENOCARCINOMA; AGED; BIOSYNTHESIS; BLOOD; BONE TUMOR; CANCER GRADING; DISEASE COURSE; HUMAN; MALE; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SECONDARY; THAILAND; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; MALE; MATRIX METALLOPROTEINASE 11; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; THAILAND; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880360710     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.3331     Document Type: Article

References (40)

1. Ahmad A, Hanby A, Dublin E, et al (1998). Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol, 152, 721-8.
2. Alexander CM, Werb Z (1991). Extracellular matrix degradation. In 'Cell Biology of Extracellular Matrix', Ed. Hay ED. Plenum Press, New York, 255-302.
3. Andarawewa KL, Boulay A, Masson R, et al (2003). Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res, 63, 5844-9.
4. Arora S, Kaur J, Sharma C, et al (2005). Stromelysin 3, Ets- 1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation withmicrovessel density, progression, and prognosis. Clin Cancer Res, 11, 2272-84.
5. Basset P, Bellocq JP, Wolf C, et al (1990). A novel Metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature, 348, 699-704.
6. Basset P, Wolf C, Chambon P (1993). Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat, 24, 185-93.
7. Bergers G, Brekken R, McMahon G, et al (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol, 2, 737-44.
8. Boulay A, Masson R, Chenard MP, et al (2001). High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res, 61, 2189-93.
9. Chen YT, Chen WT, Huang WT, et al (2012). Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans. Kaohsiung J Med Sci, Oct; 28,545-9.
10. Chenard MP, O'Siorain L, Shering S, et al (1996). High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer, 69, 448-51.
11. Cheng CW, Yu JC, Wang HW, et al (2010). The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin Chim Acta, 411, 234-41.
12. Coussens LM, Tinkle CL, Hanahan D, et al (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481-90.
13. Denys H, De Wever O, Nusgens B, et al (2004). Invasion and MMP expression profile in desmoid tumours. Br J Cancer, 90, 1443-9.
14. Egeblad M, Werb Z, (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74.
15. Escaff s, Fernandez JM, Gonzalez LO, et al (2000). Study of matrix metalloproteinases and their inhibitors in prostate cancer. Bri J Cancer, 102, 922-9.
16. Fang J, Shing Y, Wiederschain D, et al (2000). Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA, 97, 3884-9.
17. Freije JM, Baibin M, Pendas AM, et al (2003). Matrix metalloproteinases and tumor progression. Adv Exp Med Biol, 532, 91-107.
18. Jamnongkan W, Techasen A, Thanan R, et al (2013). Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma. Tumor Biol, 34,695-704.
19. Hojilla CV, Mohammed FF, Khokha R, (2003). Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer, 89, 1817-21.
20. Hourihan RN, O'Sullivan GC, Morgan JG, (2003). Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res, 23, 161-5.
21. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. Ca Cancer J Clin, 61. 69-90.
22. Kettunen E, Anttila S, Seppänen JK, et al (2004) Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet, 149, 98-106.
23. Khuhaprema T, Srivatanakul P, Attasara P, et al (2010). Cancer in Thailand Volume V 2001-2003. National Cancer Institute, 5, 7-62.
24. Kren L, Goncharuk VN, Krenova Z, et al (2006). Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol, 42, 16-9.
25. Madu Co, Lu Y (2010). Novel diagnostic biomarkers for prostate cancer. J Cancer, 1, 150-77.
26. Manes S, Mira E, Barbacid MD, et al (1997). Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem, 272, 25706-12.
27. Masson R, Lefebvre O, Noël A, et al (1998). In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol. 140, 1535-41
28. Mellick AS, Blackmore D, Weinstein SR, at al (2003). An assessment of MMP and TIMP gene expression in cell lines and stroma-tumour differences in microdissected breast cancer biopsies. Tumour Biol, 24, 258-70.
29. Murphy G, Segain JP, O'Shea M, et al (1993). The 28-kDa N-terminal domain of mouse stromelysin-3-has the general properties of a weak metalloproteinase. J Biol Chem, 268, 15435-41.
30. Parks WC, Mecham RP (1998). Matrix metalloproteinases. New York: Academic Press.
31. Pei D, Majmudar G, Weiss SJ (1994). Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem, 269, 25849-55.
32. Pei D, Weiss SJ (1995). Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature, 375, 244-7.
33. Soni S, Mathur M, Shukla NK, et al (2003). Stromelysin-3 expression is an early event in human oral tumorigenesis. Int J Cancer, 107, 309-16.
34. Sunil Kumar BV, Kumar KA, Padmanath K, et al (2013). Heterologous expression and functional characterization of matrix metalloproteinase-11 from canine mammary tumor. Anim Biotechnol, 24, 31-43.
35. Têtu B, Trudel D, Wang CS, (2006). Proteases by reactive stromal cells in cancer: an attractive therapeutic target. Bull Cancer, 93, 944-8.
36. Thorns V, Walter GF, Thorns C, (2003). Expression of MMP- 2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res, 23, 3937-44.
37. Tuamsuk P, Nonsrijun N, Pachirat K, et al (2011). Prostate cancer in Srinagarind Hospital. Srinagarind Med J, 26, 373-6.
38. Wasenius VM, Hemmer S, Kettunen E, et al (2003). Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are upregulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res, 9, 68-75.
39. Yan D, Dai H, Liu JW, (2011). Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma. BMC Cancer, 11, 151.
40. Zhao ZS, Chu YQ, Ye ZY, et al (2010). Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol, 41, 686-96.